36 results
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
29 Mar 24
SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results
9:35am
industry, has held executive positions at several healthcare companies, most recently as Chief Financial Officer of Editas Medicine.
Hosted 2023 R&D Day … and equivalents of $56.6 million at December 31, 2023, compared to $15.0 million at December 31, 2022.
R&D expenses of $16.5 million and $36.4 million
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
19 Jan 24
Regulation FD Disclosure
4:21pm
Neurotherapeutics Molecular Biologist Alexandra Kropotova, MD EVP & CHIEF MEDICAL OFFICER 20+ years global clinical development Biopharmaceutical R&D leader … , Pfizer, Wyeth, Sanofi, Teva Specialty R&D Board member, iBio Contributed to numerous patents & compounds leading portfolios from Phase I
8-K
EX-99.1
SABS
SAB Biotherapeutics Inc
31 Mar 23
SAB Biotherapeutics Provides Company Update for Full Year 2022
5:12pm
and medical affairs. Prior to joining SAB, Dr. Kropotova was the Therapeutic Area Head of Global Specialty R&D at Teva Pharmaceuticals, where she led
8-K
EX-99.1
e6zxe28tka bu3sfh
21 Nov 22
Regulation FD Disclosure
4:46pm
8-K
EX-99.1
8tqam
23 Sep 22
Regulation FD Disclosure
8:59am
424B3
bv8a tfn3t
17 Aug 22
Prospectus supplement
5:29pm
8-K
EX-99.1
aiz5me ilaktiddl
11 Jul 22
Submission of Matters to a Vote of Security Holders
9:11am
8-K
EX-99.1
pgt 9uxr00
5 Jul 22
Regulation FD Disclosure
4:31pm
424B3
iachoh
6 Jun 22
Prospectus supplement
7:02pm
8-K
e0ums
6 Jun 22
Other Events
1:35pm
8-K
EX-99.1
4oysjz71 0kmo8
6 Jun 22
Other Events
1:35pm
424B3
ntcd59tox 1ojl
13 May 22
Prospectus supplement
6:43pm